6598

Applied BioCodeTWSE:6598 Stock Report

Market Cap

NT$3.0b

7D

-2.2%

1Y

-70.0%

Updated

20 Sep, 2021

Data

Company Financials
6598 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

6598 Overview

Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex testing products for the In-Vitro diagnostics market.

Rewards

Earnings have grown 16.6% per year over the past 5 years

Risk Analysis

No risks detected for 6598 from our risk checks.

Applied BioCode Competitors

Abbott Laboratories

NYSE:ABT

US$224.8b

Becton Dickinson

NYSE:BDX

US$75.2b

Hologic

NasdaqGS:HOLX

US$19.7b

bioMérieux

ENXTPA:BIM

€13.6b

Price History & Performance

Summary of all time highs, changes and price drops for Applied BioCode
Historical stock prices
Current Share PriceNT$36.40
52 Week HighNT$36.10
52 Week LowNT$125.00
Beta0.27
1 Month Change-1.22%
3 Month Change-23.04%
1 Year Change-70.04%
3 Year Change-13.54%
5 Year Changen/a
Change since IPO-47.63%

Recent News & Updates

Mar 31
We're Interested To See How Applied BioCode (TPE:6598) Uses Its Cash Hoard To Grow

We're Interested To See How Applied BioCode (TPE:6598) Uses Its Cash Hoard To Grow

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Feb 03
Introducing Applied BioCode (TPE:6598), A Stock That Climbed 11% In The Last Three Years

Introducing Applied BioCode (TPE:6598), A Stock That Climbed 11% In The Last Three Years

The last three months have been tough on Applied BioCode Corporation ( TPE:6598 ) shareholders, who have seen the share...

Shareholder Returns

6598TW Medical EquipmentTW Market
7D-2.2%0.4%-1.1%
1Y-70.0%4.6%33.6%

Return vs Industry: 6598 underperformed the TW Medical Equipment industry which returned 4.6% over the past year.

Return vs Market: 6598 underperformed the TW Market which returned 33.6% over the past year.

Price Volatility

Is 6598's price volatile compared to industry and market?
6598 volatility
6598 Beta0.27
Industry Beta0.94
Market Beta1

Stable Share Price: 6598 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 6598's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016n/aWinston Hohttps://www.apbiocode.com

Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex testing products for the In-Vitro diagnostics market. The company’s products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. It also develops assays, such as BioCode gastrointestinal (GI) pathogen panels for common GI pathogens, including viruses, bacteria, and parasites that cause infectious diarrhea; and BioCode sexually transmitted infections (STI) panels for detection of common infectious agents causing STDs, as well as MDx assays pipeline for various molecular tests.

Applied BioCode Fundamentals Summary

How do Applied BioCode's earnings and revenue compare to its market cap?
6598 fundamental statistics
Market CapNT$2.97b
Earnings (TTM)-NT$54.19m
Revenue (TTM)NT$387.57m

7.7x

P/S Ratio

-54.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6598 income statement (TTM)
RevenueNT$387.57m
Cost of RevenueNT$140.30m
Gross ProfitNT$247.28m
ExpensesNT$301.47m
Earnings-NT$54.19m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.66
Gross Margin63.80%
Net Profit Margin-13.98%
Debt/Equity Ratio0%

How did 6598 perform over the long term?

See historical performance and comparison

Valuation

Is Applied BioCode undervalued compared to its fair value and its price relative to the market?

3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6598's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 6598's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 6598 is unprofitable, so we can't compare its PE Ratio to the TW Medical Equipment industry average.

PE vs Market: 6598 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6598's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6598 is overvalued based on its PB Ratio (3x) compared to the TW Medical Equipment industry average (2.1x).


Future Growth

How is Applied BioCode forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Applied BioCode has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Applied BioCode performed over the past 5 years?

16.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6598 is currently unprofitable.

Growing Profit Margin: 6598 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6598 is unprofitable, but has reduced losses over the past 5 years at a rate of 16.6% per year.

Accelerating Growth: Unable to compare 6598's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6598 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (9.5%).


Return on Equity

High ROE: 6598 has a negative Return on Equity (-5.47%), as it is currently unprofitable.


Financial Health

How is Applied BioCode's financial position?


Financial Position Analysis

Short Term Liabilities: 6598's short term assets (NT$925.9M) exceed its short term liabilities (NT$72.6M).

Long Term Liabilities: 6598's short term assets (NT$925.9M) exceed its long term liabilities (NT$54.0M).


Debt to Equity History and Analysis

Debt Level: 6598 is debt free.

Reducing Debt: 6598 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6598 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6598 has sufficient cash runway for 3 years if free cash flow continues to grow at historical rates of 7% each year.


Dividend

What is Applied BioCode current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6598's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6598's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6598's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6598's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6598's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average board tenure


CEO

Winston Ho

no data

Tenure

Dr. Winston Z. Ho, Ph.D. is Founder of Applied BioCode Corporation and serves as its President, Chief Technology Officer. Dr. Ho is the Founder of Applied BioCode, Inc. and serves as its President. Dr. Ho...


Board Members

Experienced Board: 6598's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Applied BioCode Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Applied BioCode Corporation
  • Ticker: 6598
  • Exchange: TWSE
  • Founded: 2016
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: NT$2.974b
  • Shares outstanding: 81.70m
  • Website: https://www.apbiocode.com

Location

  • Applied BioCode Corporation
  • 10020 Pioneer Boulevard
  • Suite 102
  • Santa Fe Springs
  • California
  • 90703
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/20 08:33
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.